LYMPHATIC MALFORMATIONS
Clinical trials for LYMPHATIC MALFORMATIONS explained in plain language.
Never miss a new study
Get alerted when new LYMPHATIC MALFORMATIONS trials appear
Sign up with your email to follow new studies for LYMPHATIC MALFORMATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Matched conditions: LYMPHATIC MALFORMATIONS
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could shrink abnormal vessels in rare childhood disorders
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …
Matched conditions: LYMPHATIC MALFORMATIONS
Phase: PHASE3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug trial aims to shrink painful lymphatic growths in kids and adults
Disease control Recruiting nowThis study tests alpelisib, a drug that targets a specific gene mutation (PIK3CA), in people with lymphatic malformations—abnormal growths of lymph vessels. The trial includes children and adults and compares alpelisib to a placebo to see if it can shrink the growths and ease sym…
Matched conditions: LYMPHATIC MALFORMATIONS
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC